TSE:4506Pharmaceuticals
Do Sumitomo Pharma's (TSE:4506) Hematology Updates Hint At A Deeper R&D Repositioning?
Sumitomo Pharma America recently presented early clinical and translational findings at the European Hematology Association 2026 Congress, including preliminary data on its investigational PIM1 inhibitor nuvisertib combined with momelotinib in myelofibrosis patients with anemia and new research on resistance mechanisms to the menin inhibitor enzomenib in acute leukemia.
By pairing encouraging response signals in a difficult-to-treat myelofibrosis population with deeper genetic insights into...